NCT01726933

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

A Multi-center, Randomized, Double-blind, Three-arm, 16 Week, Adaptive Phase III Clinical Study to Investigate the Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 839 (actual)
• Sponsor: Almirall, S.A. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	LAS41008	gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
DRUG	LASW1835	gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
DRUG	Placebo	gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

Timeline

• Start date: 2012-11-01
• Primary completion: 2014-10-01
• Completion: 2015-11-01
• First posted: 2012-11-15
• Last updated: 2015-12-02

Locations

4 sites across 4 countries: Austria, Germany, Netherlands, Poland